1086390-83-1

Basic information

• Product Name: 1H-Pyrrolo[2,3-b]pyridine-4-carboxamide
• Synonyms: 1H-Pyrrolo[2,3-b]pyridine-4-carboxamide
• CAS NO: 1086390-83-1
• Molecular Formula: C8H7N3O
• Molecular Weight: 161.16068
• Mol File: 1086390-83-1.mol
• Article Data: 2

Chemical Properties

• Appearance: /
• Density: 1.416±0.06 g/cm3(Predicted)
• PKA: 12.92±0.40(Predicted)
• CAS DataBase Reference: 1H-Pyrrolo[2,3-b]pyridine-4-carboxamide(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Pyrrolo[2,3-b]pyridine-4-carboxamide(1086390-83-1)
• EPA Substance Registry System: 1H-Pyrrolo[2,3-b]pyridine-4-carboxamide(1086390-83-1)

Safety Data

• Hazard Codes: Xn
• Statements: 22-36
• Safety Statements: 26
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 1086390-83-1(Hazardous Substances Data)

Usage

General Description

1H-Pyrrolo[2,3-b]pyridine-4-carboxamide is a chemical compound with the molecular formula C9H7N3O. It is a heterocyclic compound containing a pyrrolopyridine ring system with a carboxamide functional group. 1H-Pyrrolo[2,3-b]pyridine-4-carboxamide has potential pharmaceutical applications and is under investigation for its therapeutic properties. It may have uses in the development of drugs to treat various medical conditions, including cancer, inflammatory diseases, and neurological disorders. Research is ongoing to explore the full range of potential applications for 1H-Pyrrolo[2,3-b]pyridine-4-carboxamide in the medical and pharmaceutical fields.

Upstream product

• 344327-11-3 1H-pyrrolo[2,3-b]pyridine-4-carbonitrile 
• 479553-01-0 1H-pyrrolo[2,3-b]pyridine-4-carboxylic acid 

Relevant articles and documents

Discovery of 2-(cyclopropanecarboxamido)-N-(5-((1-(4-fluorobenzyl)piperidin-4-yl)methoxy)pyridin-3-yl)isonicotinamide as a potent dual AChE/GSK3β inhibitor for the treatment of Alzheimer's disease: Significantly increasing the level of acetylcholine in the brain without affecting that in intestine

Acetylcholinesterase (AChE) inhibitors are currently the first-line drugs approved by the FDA for the treatment of Alzheimer's disease (AD). However, a short effective-window limits their therapeutic benefits. Clinical studies have confirmed that the combination of AChE inhibitors and neuroprotective agents exhibits better anti-AD effects. We have previously reported that the dual AChE/GSK3β (Glycogen synthase kinase 3β) modulators have both neuroprotective effects and cognitive impairment-improvement effects. In this study, we characterized a new backbone of the AChE/GSK3β inhibitor 11c. It was identified as a highly potent AChE inhibitor and was found superior to donepezil, the first-line drug for the treatment of AD. In vivo studies confirmed that 11c significantly inhibited the activity of AChE in the brain but had little effect on the activity of AChE in the intestine. This advantage of 11c was expected to reduce the peripheral side effects caused by donepezil. Furthermore, biomarker studies have shown that 11c also improved the levels of acetylcholine and synaptophysin in the brain and exhibited neuroprotective effects. Preliminary in vivo and in vitro research results underline the exciting potential of compound 11c in the treatment of AD.